RLYP

Relypsa Inc.

Healthcare


Presented:02/27/2015
Price:$38.80
Cap:$1.57B
Current Price:$31.99
Cap:$1.44B

Presented

Date02/27/2015
Price$38.80
Market Cap$1.57B
Ent Value$1.44B
P/E RatioN/A
Book Value$3.66
Div YieldN/A
Shares O/S40.42M
Ave Daily Vol1,360,000
Short Int5.46%

Current

Price$31.99
Market Cap$1.44B
Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.

Publicly traded companies mentioned herein: Relypsa Inc (RLYP), ZS Pharma Inc (ZSPH)

Highlights

Relypsa (RLYP) just announced the pricing of its offering of 3.9 million shares at $38.50 (2/25/15) and the presenter thinks the timing and risk/ reward setup are favorable on the long side. RLYP’s management team is very credible, and the lead product candidate - Patiromer for treatment of hyperkalemia - recently completed its Phase III trial under SPA (the PDUFA date is scheduled for October 21, 2015). The total addressable market for potassium reducing/ control agents is large (~2-2.5 million patients in the US), and the presenter believes Patiromer could be a $900 million to $1 billion per year opportunity.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.